Edgar Filing: Daniel William F - Form 4

Form 4	am F										
September 20										PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								3235-028			
Check thi if no long	or	box								January 31 2005	
subject to Section 1 Form 4 or	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP O SECURITIES								Estimated average burden hours per response		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								n			
(Print or Type R	Responses)										
1. Name and Address of Reporting Person <u>*</u> Daniel William F			2. Issuer Name and Ticker or Trading Symbol					5. Relationship of Reporting Person(s) to Issuer			
			Horizon Pharma plc [HZNP]					(Check all applicable)			
(Last) (First) (Middle) C/O HORIZON PHARMA PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD			3. Date of Earliest Transaction (Month/Day/Year) 09/19/2017					X_ Director 10% Owner Officer (give title Other (specify below) below)			
				mendment, Date Original Aonth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
DUBLIN, L	24							Form filed by M Person	fore than One Re	eporting	
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative	Secur	ities Aco	quired, Disposed of	, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)2. Transaction (Month/Day, (Instr. 3)		any		3.4. Securities AcquiredTransaction(A) or Disposed ofCode(D)(Instr. 8)(Instr. 3, 4 and 5)				Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)			
Ordinary Shares	09/19/2017			М	7,874	А	<u>(1)</u>	32,262	I	By Trust	
Ordinary Shares	09/19/2017			F	2,381	D	\$ 12.1	29,881	I	By Trust	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Daniel William F - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Code			6. Date Exerce Expiration D (Month/Day/	Date	of Underlyin Securities	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
			Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Stock Units	<u>(1)</u>	09/19/2017	М		7,874	(2)	(2)	Ordinary Shares	7,874	\$

Reporting Owners

Reporting Owner Name / Address		Relationships					
	Director	10% Owner	Officer	Other			
Daniel William F C/O HORIZON PHARMA PLC CONNAUGHT HOUSE, 1ST FL, 1 H DUBLIN, L2 4	Х						
Signatures							
/s/ Miles W. McHugh, Attorney-in-Fact	09/20/2017						
**Signature of Reporting Person	Date						

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- (2) The restricted stock units vest in three equal annual installments on each anniversary of the vesting commencement date (September 19, 2014).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.